'Safety endpoint' diaporamas de présentation

Medtronic RDN SYMPLICITY HTN-3

Medtronic RDN SYMPLICITY HTN-3. Key Takeaways. SYMPLICITY HTN-3 did not reach the primary or powered secondary efficacy endpoints in this trial. There may be many factors that contributed to the outcome, which we continue to investigate .

609 views • 32 slides

Extract: Protocol Design

Extract: Protocol Design. STEMI < 6 h Lytic eligible. Lytic choice by MD (TNK, tPA, rPA, SK). ASA. Double-blind, double-dummy. ENOX < 75 y: 30 mg IV bolus SC 1.0 mg / kg q 12 h (Hosp DC) ? 75 y: No bolus SC 0.75 mg / kg q 12 h (Hosp DC ) CrCl < 30: 1.0 mg / kg q 24 h.

321 views • 26 slides

Clinical/Surrogate Endpoints and Innovative Approaches for Catheter Ablation Studies

105 views • 10 slides